These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27037644)

  • 1. Liposomal Amphotericin B drug access for the treatment of leishmaniasis in Brazil.
    Mistro S; Rodrigues M; Rosa L; Camargo M; Badaró R
    Trop Med Int Health; 2016 Jun; 21(6):692-3. PubMed ID: 27037644
    [No Abstract]   [Full Text] [Related]  

  • 2. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of visceral Leismaniasis in HIV patients with a new regimen of liposomal amphotericin].
    Canora Lebrato J; Troncoso García E; Escobar T; Hernández Quero J
    Med Clin (Barc); 2001 Mar; 116(10):395. PubMed ID: 11333677
    [No Abstract]   [Full Text] [Related]  

  • 4. Visceral leishmaniasis in an infant gorilla (Gorilla gorilla gorilla): Clinical signs, diagnosis, and successful treatment with single-dose liposomal amphotericin B.
    Tinoco HP; da Costa MELT; Pessanha AT; Coelho CM; de Carvalho TF; Mol JPDS; Viana AG; Bueno LL; Fujiwara RT; Santos RL
    J Med Primatol; 2018 Dec; 47(6):416-418. PubMed ID: 29956831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients.
    Petit N; Parola P; Dhiver C; Gastaut JA
    J Antimicrob Chemother; 1996 Jul; 38(1):154-7. PubMed ID: 8858471
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of visceral leishmaniasis with liposomal amphotericin B in three immunocompromised patients].
    Rodríguez-Wilhelmi P; Panizo C; Ruza E; Rocha E
    Med Clin (Barc); 2001 Jan; 116(1):37-8. PubMed ID: 11181264
    [No Abstract]   [Full Text] [Related]  

  • 8. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Berman JD
    Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
    [No Abstract]   [Full Text] [Related]  

  • 10. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
    Vigna E; De Vivo A; Gentile M; Morelli R; Lucia E; Mazzone C; Recchia AG; Vianelli N; Morabito F
    Transpl Infect Dis; 2010 Oct; 12(5):428-31. PubMed ID: 20534035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eliminating visceral leishmaniasis in South Asia: the road ahead.
    Rijal S; Sundar S; Mondal D; Das P; Alvar J; Boelaert M
    BMJ; 2019 Jan; 364():k5224. PubMed ID: 30670453
    [No Abstract]   [Full Text] [Related]  

  • 12. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current issues in the treatment of visceral leishmaniasis.
    Bryceson A
    Med Microbiol Immunol; 2001 Nov; 190(1-2):81-4. PubMed ID: 11770117
    [No Abstract]   [Full Text] [Related]  

  • 14. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
    Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
    Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
    Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A
    BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
    Dilber E; Erduran E; Işik Y
    Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visceral Leishmaniasis-Optimum Treatment Options in Children.
    Sundar S; Agarwal D
    Pediatr Infect Dis J; 2018 May; 37(5):492-494. PubMed ID: 29280784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term remission of human immunodeficiency virus-associated visceral leishmaniasis after initiation of potent combination antiretroviral treatment: report of two cases.
    Mastroianni CM; d'Ettorre G; Forcina G; Corpolongo A; Dell'Isola S; Lichtner M; D'Agostino C; Trinchieri V; Santopadre P; Vullo V
    J Infect; 2000 Jan; 40(1):94-6. PubMed ID: 10762121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.
    Seifert K; Juhls C; Salguero FJ; Croft SL
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5819-23. PubMed ID: 26055371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India.
    Pandey K; Pal B; Siddiqui NA; Rabi Das VN; Murti K; Lal CS; Verma N; Babu R; Ali V; Kumar R; Das P
    Am J Trop Med Hyg; 2017 Nov; 97(5):1498-1502. PubMed ID: 29016288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.